Issue Archive

This Blood Spotlight highlights the background and recent data surrounding the use of the recently approved interferon-γ neutralizing antibody emapalumab, Gamifant, for the treatment of hemophagocytic lymphohistiocytosis.

In this review, the authors describe 3 patients with common variable immunodeficiency (CVID), noting the disease manifestations most relevant to the practicing hematologist, especially autoimmune cytopenias, benign lymphoproliferation, granulomatous disease, and lymphomas such as common noninfectious complications of CVID.

This article provides a comprehensive review of the first-line therapy in the rapidly evolving field of chronic lymphocytic leukemia (CLL).

In this How I Treat article, the authors describe their clinical approach to this rapidly available transplantation platform and address some of the key clinical questions associated with its use.

This article presents a comprehensive genetic, clinical, and drug sensitivity analysis of a large series of B-prolymphocytic leukemia cases, illustrating new findings with implications for predicting clinical outcomes and suggesting novel targets for therapy.

This article reports metabolic consequences of JAK2-mutant myeloproliferative neoplasms (MPNs) with a therapeutic translational impact: expression of mutant JAK2 induces abnormal metabolic activity of MPN cells, resulting in hypoglycemia, adipose tissue atrophy, and early mortality.

The investigators explore the role of PDK1 (phosphoinositide-dependent protein kinase 1) in the cytoskeletal regulation of platelet production and furnish new insights into megakaryocyte maturation and proplatelet formation.

This study uses genetic and pharmacologic approaches to demonstrate novel roles of eosinophils in the progression of atherosclerosis and arterial thrombosis.